Effect and Safety of ior® EPOCIM in patients with Non-Hodking Lymphoma treated with anthracyclines.
Phase 2
Suspended
- Conditions
- Patients with Non-Hodking Lymphoma
- Registration Number
- RPCEC00000096
- Lead Sponsor
- Center of Molecular Immunology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
.Patients who met the diagnostic criteria.
.Patients of either sex with age greater than or equal to 18 years.
.Patients who give informed consent to participate in writing.
.Patients with hemoglobin below 13 g/dl.
Exclusion Criteria
.Patients with uncontrolled hypertension.
.Patients with known risk or a history of venous or arterial thromboembolic disease.
.Severe cardiovascular disease:unstable angina,heart failure,aortic stenosis,endocarditis.
.Patients with poor acoustic window.
.Severe cerebrovascular disease. .Septic embolism.
.Chronic myeloproliferative diseases.
.Patients with known hypersensitivity to products derived from higher cells or hypersensitivity to human albumin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method